Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M F Brady

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 13, 2010
The MIT D-lab electricity-free PortaTherm™ incubator for remote testing with the QuantiFERON®-TB Gold In-Tube assayM Dominguez, A Smith, G Luna, et al.
American Journal of Obstetrics and Gynecology|April 1, 1994
The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinomaW J Hoskins, W P McGuire, M F Brady, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1996
Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125G J Rustin, A E Nelstrop, P McClean, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2001
Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group studyP M Fracasso, M F Brady, D H Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1995
Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a Gynecologic Oncology Group studyD R Barnhill, R J Kurman, M F Brady, et al.
Cancer|February 15, 1993
Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group studyF J Major, J A Blessing, S G Silverberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology GroupJ T Thigpen, M F Brady, R D Alvarez, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|November 20, 2008
Reducing the string test intra-gastric downtime for detection of Mycobacterium tuberculosisW H Bae, A Salas, M F Brady, et al.
The New England Journal of Medicine|January 4, 1996
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancerW P McGuire, W J Hoskins, M F Brady, et al.
Seminars in Oncology|February 1, 1997
Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group studyW P McGuire, W J Hoskins, M F Brady, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 13, 2010
The MIT D-lab electricity-free PortaTherm™ incubator for remote testing with the QuantiFERON®-TB Gold In-Tube assayM Dominguez, A Smith, G Luna, et al.
American Journal of Obstetrics and Gynecology|April 1, 1994
The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinomaW J Hoskins, W P McGuire, M F Brady, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1996
Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125G J Rustin, A E Nelstrop, P McClean, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2001
Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group studyP M Fracasso, M F Brady, D H Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1995
Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a Gynecologic Oncology Group studyD R Barnhill, R J Kurman, M F Brady, et al.
Cancer|February 15, 1993
Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group studyF J Major, J A Blessing, S G Silverberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology GroupJ T Thigpen, M F Brady, R D Alvarez, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|November 20, 2008
Reducing the string test intra-gastric downtime for detection of Mycobacterium tuberculosisW H Bae, A Salas, M F Brady, et al.
The New England Journal of Medicine|January 4, 1996
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancerW P McGuire, W J Hoskins, M F Brady, et al.
Seminars in Oncology|February 1, 1997
Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group studyW P McGuire, W J Hoskins, M F Brady, et al.
Pageof 5